Delivering innovative translational precision medicine research at the University of Leicester
Lead Research Organisation:
University of Leicester
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
Previous funding from five consecutive Confidence in Concept (CiC) awards, together with strategic investment from the University of Leicester, has generated a sustainable pipeline of projects successfully consolidating and expanding our translational research capabilities. This is evidenced by a 9:1 return on investment from CiC funding (>£12 M). A key advance in the last twelve months has been the rebalancing of the projects across the translation pipeline to increase diagnostic and device development projects, whilst also supporting projects later in the pipeline, e.g. the assessment of ‘breathomics’ and related blood biomarkers of patient response to treatment. In addition our mature projects are now beginning to deliver real world benefits for patients, e.g. having recently delivered an intervention into a first in man clinical trial. The successful delivery of CiC funded translational research projects into healthcare has been accelerated through enhanced interactions with the Leicester Precision Medicine Institute and the University Hospitals of Leicester NHS Trust, plus engagement with major strategic awards from MRC/EPSRC Molecular Pathology node, the NIHR Biomedical Research Centre, CRUK/DoH Experimental Cancer Medicine Centre and the Clinical Research Facility in Emergency Medicine. The award of the next phase of MRC CiC funding will enable us to further enhance our portfolio of projects to deliver novel diagnostics and therapeutic interventions in collaboration with key industrial partners to improve patient outcomes. We will capitalise on innovative translational opportunities that align with the AI & Data Economy and Ageing Society ‘Grand Challenges’ (from the Life Sciences Sector Deal). This strategic alignment will be supported by pumppriming interdisciplinary collaborations that implement artificial intelligence approaches in diagnostics and exploit our leading position as an academic AI Powerhouse (1 of only 3 in the UK). The CiC will be complemented by targeted support from the University’s Research and Enterprise Division, plus engagement with Science Park Leicester and the Innovation Hub to maximise follow on funding translational opportunities (through UKRI) and business engagement. Close linkage with Midlands Engine partners will enable us to support our colleagues to develop the translational skills that will support the growth of the Life Science sector within the Midlands region.
Organisations
- University of Leicester (Lead Research Organisation)
- Foundation for Innovative New Diagnostics (FIND) (Collaboration)
- Inotrem SA (Collaboration)
- Leica Microsystems GmbH (Collaboration)
- QuantuMDx Group Ltd. (Collaboration)
- 42 Technology (Collaboration)
- UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST (Collaboration)
- Waters Corporation (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Luminex Corporation (Collaboration)
- Galecto Biotech (Collaboration)
- LifeArc (Collaboration)
- Oxford Immunotec Global (Collaboration)
- THE PIRBRIGHT INSTITUTE (Collaboration)
- NIHR Health Protection Research Unit (Collaboration)
- Medical Research Council (MRC) (Collaboration)
People |
ORCID iD |
Publications
Kuht HJ
(2020)
SLC38A8 mutations result in arrested retinal development with loss of cone photoreceptor specialization.
in Human molecular genetics
Mahase E
(2020)
Covid-19: Universities roll out pooled testing of students in bid to keep campuses open.
in BMJ (Clinical research ed.)
Garcia-Cruz A
(2020)
Generic sensor platform based on electro-responsive molecularly imprinted polymer nanoparticles (e-NanoMIPs).
in Microsystems & nanoengineering
Smalley JP
(2020)
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
in Chemical communications (Cambridge, England)
Alanazi K
(2021)
Disposable paracetamol sensor based on electroactive molecularly imprinted polymer nanoparticles for plasma monitoring
in Sensors and Actuators B: Chemical
Smalley JP
(2022)
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.
in Journal of medicinal chemistry
Van Puyvelde B
(2022)
Cov2MS: An Automated and Quantitative Matrix-Independent Assay for Mass Spectrometric Measurement of SARS-CoV-2 Nucleocapsid Protein.
in Analytical chemistry
Kuht HJ
(2022)
Genotypic and Phenotypic Spectrum of Foveal Hypoplasia: A Multicenter Study.
in Ophthalmology
Blackmore C
(2022)
How to design and implement a university-based COVID-19 testing programme? An evaluation of a novel RT-LAMP COVID-19 testing programme in a UK university.
in BMC health services research
Hällqvist J
(2023)
Operation Moonshot: rapid translation of a SARS-CoV-2 targeted peptide immunoaffinity liquid chromatography-tandem mass spectrometry test from research into routine clinical use.
in Clinical chemistry and laboratory medicine
Baker IM
(2023)
Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs).
in Biochemistry
Pan D
(2023)
Exhaled SARS-CoV-2 RNA viral load kinetics measured by facemask sampling associates with household transmission.
in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
| Description | BHF Accelerator Award (Leicester) |
| Amount | £20,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 05/2021 |
| Description | Developing a Prototype Artificial Intelligence-based Eye Tracker (A-EYE) for the Diagnosis and Monitoring of Eye Movement Disorders |
| Amount | £14,884 (GBP) |
| Organisation | Fight for Sight |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2020 |
| Description | Development of Mass Spectrometry for diagnosis of Covid-19 |
| Amount | £3,000,000 (GBP) |
| Organisation | Government of the UK |
| Department | Department of Health and Social Care |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 02/2021 |
| Description | MC_PC_MR/X012565/1 MRC equipment award |
| Amount | £321,969 (GBP) |
| Funding ID | MC_PC_MR/X012565/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2022 |
| Description | Medical and biological significance of exhaled M. tuberculosis detected by community level face mask sampling in Pretoria. |
| Amount | £537,490 (GBP) |
| Funding ID | MR/T031255/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2020 |
| End | 01/2022 |
| Description | Optical Coherence Tomography in Children |
| Amount | £247,312 (GBP) |
| Organisation | Ulverscroft Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 12/2022 |
| Description | Understanding the unique properties of the Sin3A Histone deacetylase complex in transcription and cell viability |
| Amount | £978,861 (GBP) |
| Funding ID | MR/W00190X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2025 |
| Description | Use of mask sampling using vacuum formed Masks - South Africa |
| Amount | £150,030 (GBP) |
| Organisation | World Health Organization (WHO) |
| Sector | Public |
| Country | Global |
| Start | 10/2020 |
| End | 03/2021 |
| Title | Application of Artificial Intelligence in Paediatric Ophthalmology - a pilot study |
| Description | A database of paediatric optical coherence tomography (OCT) scans which contains images of children retinas. The database contains scans from normal controls and children with retinal abnormalities.The project is supporting full annotation of the scans. In the process of seeking FDA approval as a validation set for new OCT hard- and software. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | The database under development will facilitate a multi-end point searchable database to be used as a learning and test data sets for the developed algorithm. Outputs will aim to provide earlier detection of retinal abnormalities and the earlier diagnosis of genetic disease leading to differential treatment outcomes and better prognosis for a range of eye and other physiological abnormalities with genetic components. |
| Description | ATACCC (Assessment of Transmission and Contagiousness of COVID-19 Contacts) - mask sampling |
| Organisation | NIHR Health Protection Research Unit |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Prof Barer is an expert in the manufacture and analysis of mask mounted capture strips for exhaled microorganisms. |
| Collaborator Contribution | NIHR HPRU are undertaking a study of Covid transmission risk in human volunteers - they requested capture masks and analysis from Leicester |
| Impact | No outputs as yet. |
| Start Year | 2020 |
| Description | Application of Artificial Intelligence in Paediatric Ophthalmology - a pilot study |
| Organisation | Leica Microsystems GmbH |
| Country | Germany |
| Sector | Private |
| PI Contribution | The research team at Leicester is at the forefront of paediatric OCT imaging and have previously published seminal papers in the field. One of our landmark papers is on the classification of retinal development disorders (foveal hypoplasia) which allows clinicians to grade, diagnose and provide prognosis for children with arrested retinal development. Gave access to the largest reference dataset for paediatric OCTs worldwide. |
| Collaborator Contribution | MTA signed in 2019 to allow Leica to share the code for their software. This will allow direct access to the encrypted images from the scans so it could be used for the AI system (training, optimization and validation). This would also allow batch processing and thus scaling up the dataset further. Leica are interested in further collaboration, but are awaiting data from the PI, which is expected in July 2020. |
| Impact | 3x 1 year NIHR academic foundation trainee posts - to perform segmentation of scans and developing AI-based technique for segmentation. NIHR Academic clinical fellowship. Scoping with industrial partners (e.g. Translational Imaging Innovations). Gave confidence for follow-on funding (MC_PC_18054). |
| Start Year | 2019 |
| Description | Application of a phage-PCR based technology to develop novel diagnostic tools for Tuberculosis |
| Organisation | Luminex Corporation |
| Department | Luminex (Canada) |
| Country | Canada |
| Sector | Private |
| PI Contribution | The capability to conduct a prospective cohort study with TB and non-TB patients. Provide access to patient samples and identify eligible samples for recruitment. |
| Collaborator Contribution | Collaborators in Nottingham hold the I.P. for the assay methodology used which has been licenced to the SME biotechnology company, PBD Biotech Ltd (who are partly owned by University of Nottingham). PBD Biotech have agreed to cover the labour costs of performing the tests (In-kind contribution). Luminex contribution: will place a proprietary platform for developmental work at UoL and UoN and provide support for platform adaptation (in-kind value unknown). Oxford Immunotec are contributing expertise and equipment to enable automation of the assay- by automating the separation of lymphocytes from whole blood. |
| Impact | None to date. (Reviewed March 2021 - Updated march 2021) |
| Start Year | 2019 |
| Description | Application of a phage-PCR based technology to develop novel diagnostic tools for Tuberculosis |
| Organisation | Oxford Immunotec Global |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The capability to conduct a prospective cohort study with TB and non-TB patients. Provide access to patient samples and identify eligible samples for recruitment. |
| Collaborator Contribution | Collaborators in Nottingham hold the I.P. for the assay methodology used which has been licenced to the SME biotechnology company, PBD Biotech Ltd (who are partly owned by University of Nottingham). PBD Biotech have agreed to cover the labour costs of performing the tests (In-kind contribution). Luminex contribution: will place a proprietary platform for developmental work at UoL and UoN and provide support for platform adaptation (in-kind value unknown). Oxford Immunotec are contributing expertise and equipment to enable automation of the assay- by automating the separation of lymphocytes from whole blood. |
| Impact | None to date. (Reviewed March 2021 - Updated march 2021) |
| Start Year | 2019 |
| Description | Assessment and contagiousness of COVID contact (mask supply and analysis) |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Prof Barer has expertise in the production of capture strips to assess exhaled microorganisms and their analysis - these were supplied to Imperial College and analysed in Leicester |
| Collaborator Contribution | Imperial College are examining Covid infectiousness in human volunteers - they requested the masks as a way of estimating viral shedding in breath |
| Impact | No outputs. |
| Start Year | 2020 |
| Description | Creating a decoy trap to block Covid19 (ACE2 Receptor mimic) |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Laboratory of Molecular Biology (LMB) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Prof Brindle's group has expertise in in vitro evolution of binding proteins. |
| Collaborator Contribution | Dr Bailey of the Pirbright Institute contributed expertise in Covid-19 biology Dr Sale of the MRC contributed expertise in cloning and protein structures |
| Impact | Have produced four decoy proteins that block binding of Cov2 spike protein RBD to Vero cells, as well as an antagonist that blocks viral RBD protein binding. These data are being prepared for publication. (Reviewed march 2021 - Updated march 2021) |
| Start Year | 2020 |
| Description | Creating a decoy trap to block Covid19 (ACE2 Receptor mimic) |
| Organisation | The Pirbright Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Prof Brindle's group has expertise in in vitro evolution of binding proteins. |
| Collaborator Contribution | Dr Bailey of the Pirbright Institute contributed expertise in Covid-19 biology Dr Sale of the MRC contributed expertise in cloning and protein structures |
| Impact | Have produced four decoy proteins that block binding of Cov2 spike protein RBD to Vero cells, as well as an antagonist that blocks viral RBD protein binding. These data are being prepared for publication. (Reviewed march 2021 - Updated march 2021) |
| Start Year | 2020 |
| Description | Developing a translatable assay for determination of Mycobacterium tuberculosis lipid body content in sputum - a biomarker of TB treatment response |
| Organisation | QuantuMDx Group Ltd. |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We instigated the analysis of Mycobacterium tuberculosis (Mtb) Lipid Bodies (LBs) frequencies in sputum more than 20 years ago. A member of the research team has more than 5 years' practical experience of this technique. We have current MRC funding to validate LBs as a biomarker of treatment response and will analyse ~300 patient sputum samples from the RIFASHORT TB clinical trial through this. We have extensive experience examining different lipid fluorophores by microscopy, utilising the characteristic wavelength emission shift of Nile Red in LBs to improve determination of LB content in pure culture and to demonstrate the potential of plate-based fluorometric analysis of lipid content. |
| Collaborator Contribution | QuantuMDx have developed proprietary sputum lytic protocols and Capture-XT to selectively capture, clean and concentrate Mtb. QuantuMDx research staff will provide expertise for any project-specific optimisation of Capture-XT parameters if required for optimal performance for the needs of this project. We are confident that by combining the expertise and technology of both teams we will be able to deliver an assay with greater potential for translation. |
| Impact | This project links P2D and CiC funding - CiC funding as a follow on from the discussions and person exchange initiated by P2D award. This project has been affected by COVID as lead scientist (Jonathan Decker) has been seconded to another project supporting COVID diagnostic research. Work is expected to re-commence on this project mid 2021. The relationship wit QuantuMDx is ongoing. Reviewed March 2021. |
| Start Year | 2019 |
| Description | Development of Ang2-selective ligand-trap |
| Organisation | Inotrem SA |
| Country | France |
| Sector | Private |
| PI Contribution | Development and validation of high affinity ligand trap system for human Ang2. Molecular 'know how' to test the affinity for mouse model being developed by Inotrem. Set up for the production of trap proteins for validation by Inotrem. |
| Collaborator Contribution | Inotrem: Developed mouse model of sepsis, anti-sepsis small molecule. LifeArc: patent and commercailisation rights to Ang2 ligand trap system (joint owned with UoL). |
| Impact | Biophysical screening for selectivity and affinity complete - Ang2 trap functional against mouse protein - can move towards mouse models. Licencing agreement with Inotrem. Patent approved: Publication number: WO2014096855 ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR; Patent granted in EU, US, AUS. This collaboration is ongoing and has been strengthened across two CiC awards. The relationship has just entered a more significant phase with focused delivery plans, for both parties, to move towards validation for sepsis. |
| Start Year | 2018 |
| Description | Development of Ang2-selective ligand-trap |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Development and validation of high affinity ligand trap system for human Ang2. Molecular 'know how' to test the affinity for mouse model being developed by Inotrem. Set up for the production of trap proteins for validation by Inotrem. |
| Collaborator Contribution | Inotrem: Developed mouse model of sepsis, anti-sepsis small molecule. LifeArc: patent and commercailisation rights to Ang2 ligand trap system (joint owned with UoL). |
| Impact | Biophysical screening for selectivity and affinity complete - Ang2 trap functional against mouse protein - can move towards mouse models. Licencing agreement with Inotrem. Patent approved: Publication number: WO2014096855 ANGIOPOIETIN-2 SPECIFIC TIE2 RECEPTOR; Patent granted in EU, US, AUS. This collaboration is ongoing and has been strengthened across two CiC awards. The relationship has just entered a more significant phase with focused delivery plans, for both parties, to move towards validation for sepsis. |
| Start Year | 2018 |
| Description | Face Mask Sampling for microorganism and virus detection - commercial product design |
| Organisation | 42 Technology |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Prof Barer has expertise in the manufacture and use of sterile strips for capture of exhaled Microorganisms - particularly Tuberculosis |
| Collaborator Contribution | FIND provides funding support for diagnostics applicable to developing countries. 42T are experts in design for manufacture solutions and novel medical device development. |
| Impact | No outputs as yet. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2020 |
| Description | Face Mask Sampling for microorganism and virus detection - commercial product design |
| Organisation | Foundation for Innovative New Diagnostics (FIND) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | Prof Barer has expertise in the manufacture and use of sterile strips for capture of exhaled Microorganisms - particularly Tuberculosis |
| Collaborator Contribution | FIND provides funding support for diagnostics applicable to developing countries. 42T are experts in design for manufacture solutions and novel medical device development. |
| Impact | No outputs as yet. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2020 |
| Description | Molecular characterisation of viral:host cell interactions that may underlie hyperinflammation and mortality in COVID-19 |
| Organisation | Galecto Biotech |
| Country | Sweden |
| Sector | Private |
| PI Contribution | The Leicester research group (Prof Bibek Gooptu) has expertise in analysis of the Gal-3-Fibrosome - a putative mechanism for Covid-19 mediated hyperinflammation. |
| Collaborator Contribution | Galecto possess expertise in synthesis and manufacture of small molecules targeting the Gal-3-Fibrosome - they are supplying molecules for Prof Gooptu to analyse. |
| Impact | No outputs to date. (Reviewed March 2021 - Updated March 2021) |
| Start Year | 2020 |
| Description | PHOSP-COVID MS collaboration |
| Organisation | University Hospitals of Leicester NHS Trust |
| Department | Leicester Respiratory Biomedical Research Unit |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Here, we build on our Cov-MS effort using LC-MS, adding SISCAPA technology to enrich proteotypic peptides of the SARS-CoV-2 nucleocapsid (N) protein from trypsin-digested patient samples. |
| Collaborator Contribution | Waters in-kind contributions provided to optimise the assay include: instrumentation worth £95,000, consumables (£20,000) and personnel (£20,000). |
| Impact | doi: 10.1515/cclm-2022-1000 doi: 10.1021/acs.analchem.2c01610 |
| Start Year | 2020 |
| Description | PHOSP-COVID MS collaboration |
| Organisation | Waters Corporation |
| Department | Waters Corporation |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Here, we build on our Cov-MS effort using LC-MS, adding SISCAPA technology to enrich proteotypic peptides of the SARS-CoV-2 nucleocapsid (N) protein from trypsin-digested patient samples. |
| Collaborator Contribution | Waters in-kind contributions provided to optimise the assay include: instrumentation worth £95,000, consumables (£20,000) and personnel (£20,000). |
| Impact | doi: 10.1515/cclm-2022-1000 doi: 10.1021/acs.analchem.2c01610 |
| Start Year | 2020 |
| Title | Arterial shunt |
| Description | Application for arterial shunt device filed on 9th August 2022 |
| IP Reference | 2211616.4 |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | No |
| Impact | None yet |
| Title | HDAC DEGRADER |
| Description | The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may be used to treat cancer. The invention extends to pharmaceutical compositions comprising these compounds, and the use of these compounds in therapy. |
| IP Reference | WO2021148811 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | These novel structures should give rise to the discovery and development of other chimeric compounds for the treatment of cancer. |
| Title | A near patient paracetamol test |
| Description | Development of a novel detection system suitable for near patient measurement of paracetamol. |
| Type Of Technology | Detection Devices |
| Year Produced | 2019 |
| Impact | Next phase is further development of a device format suitable to be tested in a future MRC DPFS funded project. This device will address the need for a rapid, near patient test for circulating levels of paracetamol in blood to enable early detection of overdoses, improve patient outcomes and reduce time in the Emergency Department. |
| Title | The Fail-safe Interatrial Shunt Device |
| Description | The Fail-safe Interatrial Shunt Device enables left atrial depressurisation via a left atrial pressure responsive reversible interatrial shunt to prevent decompensation leading to acute heart failure. |
| Type Of Technology | Detection Devices |
| Year Produced | 2020 |
| Impact | This approach promises to substantially reduce health care costs by further reducing acute heart failure admissions and eliminating the need for a dedicated team to monitor and respond to changes in pulmonary artery pressure signals. |
| Description | Academy of medical sciences - development and validation of a deep learning algorithm for paediatric retinal developmental disorders |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | poster presentation of development and validation of a deep learning algorithm for paediatric retinal developmental disorders |
| Year(s) Of Engagement Activity | 2019 |
| Description | Aravind eye hospital India, decoding infantile nystagmus syngrom |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited to speak and present at :Aravind eye hospital India, decoding infantile nystagmus syngrom |
| Year(s) Of Engagement Activity | 2021 |
| Description | Bringing the OCT to the patient, and not the patient to the OCT |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | 591 participants in 82 different countries engaged with the Webinar which was presented by an expert panel from the world-renowned University of Leicester Ulverscroft Eye Unit (UK) sponsored by Leica and TII: Comparisons between hand-held OCT and table-mounted OCT Clinical applications including detection and assessment of foveal and optic nerve abnormalities and monitoring of disease progression Research applications with a focus on nystagmus, childhood glaucoma, and cerebral malaria In short, discover how hand-held OCT (namely, Leica EnVisu) in ophthalmology procedures can support you in the diagnosis of physiological and pathologic conditions of the eye. (Reviewed March 2021 - Updated March 2021) |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://theophthalmologist.com/webinar/clinical-applications-of-hand-held-oct-bringing-the-oct-to-th... |
| Description | Case study detection of SARS-Covid-2 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Case study available on New England Biolabs website for LAMP for molecular diagnostics and IVD |
| Year(s) Of Engagement Activity | 2021 |
| URL | http://neb.uk.com/support/lamp-for-molecular-and-in-in-vitro-diagnostics |
| Description | Degrading Class I Histone Deacetylase Enzymes with Heterobifunctional Molecules, invited speaker at the Young Chemists 2021 symposium, Imperial College, London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker as a senior research scientist. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Deutsche opthalmologische gesellschaft - Foveal development on OCT imaging |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited speaker - Foveal development on OCT imaging |
| Year(s) Of Engagement Activity | 2021 |
| Description | Foveal development on OCT imaging at EUROTINA- European society of retinal specialists |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | invited talk on Foveal development on OCT imaging |
| Year(s) Of Engagement Activity | 2021 |
| Description | Leicester eye meeting - using AI to diffentiate between normal and abnormal retinal development |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited to speak at Leicester eye meeting - using AI to diffentialte between normal and abnormal retinal development. At Leicester Marriot hotel aiming to bring ophthalmologisst and allied health care professionals together for the purpose of education. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Altmetric 141; Dimensions score 17; Altmetric has seen 24 tweets from 22 users, with an upper bound of 27,018 followers. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://acs.altmetric.com/details/124806196/news |
| Description | Royal college of ophthalmologists - A machine learning solution to predict foveal development and visual prognosis in retinal developmental disorders |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited to speak at Royal college of ophthalmologists, virtual congress - A machine learning solution to predict foveal development and visual prognosis in retinal developmental disorders For which was awarded runner -up prize for best presentation |
| Year(s) Of Engagement Activity | 2021 |
| Description | Royal college of ophthalmologists - Genotypic and phenotypic spectrum of foveal hyperplasia |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited to speak/present at Royal college of ophthalmologists, virtual congress. Genotypic and phenotypic spectrum of foveal hyperplasia |
| Year(s) Of Engagement Activity | 2021 |
| Description | Use of AI in patients with Nystagmus |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop at Cardif (Nystagmus network) talk to promote Use of AI in patients with Nystagmus. |
| Year(s) Of Engagement Activity | 2019 |
| Description | world society of paediatric ophthalmology and strabismus WSPOS |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited speaker - How can genetic evaluation help with diagnosis and classification of INS |
| Year(s) Of Engagement Activity | 2021 |
| Description | world society of paediatric ophthalmology and strabismus WSPOS |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | invited as a speaker use of ophthalmic imaging in the diagnosis and classification of infantile nystagmus syndrome |
| Year(s) Of Engagement Activity | 2021 |